UK-432,097
From Infogalactic: the planetary knowledge core
Names | |
---|---|
IUPAC name
6-(2,2-diphenylethylamino)-9-((2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-N-(2-(3-(1-(pyridin-2-yl)piperidin-4-yl)ureido)ethyl)-9H-purine-2-carboxamide
|
|
Identifiers | |
380221-63-6 | |
Abbreviations | UK-432,097 |
ChemSpider | 8009243 |
Jmol 3D model | Interactive image Interactive image |
PubChem | 9833519 |
|
|
|
|
Properties | |
C40H47N11O6 | |
Molar mass | 777.89 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
verify (what is ?) | |
Infobox references | |
UK-432,097 is a drug developed by Pfizer for the treatment of chronic obstructive pulmonary disease, which acts as a potent and selective agonist of the adenosine A2A receptor.[1] It was discontinued from clinical trials following poor efficacy results,[2] but its high selectivity has made it useful for detailed mapping of the internal structure of the A2A receptor.[3]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease. ClinicalTrials.gov
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>
<templatestyles src="Asbox/styles.css"></templatestyles>